Attached files
| file | filename |
|---|---|
| 8-K - NEOGENOMICS INC | v208049_8-k.htm |
Exhibit
99.1
NEOGENOMICS,
INC
PRESS
RELEASE
NeoGenomics
Announces Equity Raise from
Insiders
and Existing Shareholders at $1.50/Share
Proceeds
to Strengthen Financial Position and Fund Growth Initiatives
Ft. Myers, Florida – January 12, 2011
– NeoGenomics, Inc. (NASD OTC BB: NGNM) announced today that it has
completed a $3.0 million equity financing transaction. Five members
of the Company’s Board of Directors and senior management team and two existing
institutional investors of the Company participated in the
transaction. The transaction was priced at $1.50 per share and
resulted in 2.0 million shares of new common stock being issued by the
Company. No warrants were issued and no placement agent was used in
the transaction. The Company plans to use the proceeds to strengthen
its financial position and fund growth initiatives.
Doug
VanOort, the Company’s Chairman and CEO, said the following, “We are very
pleased to announce this transaction. The fact that insiders and
existing institutional shareholders are willing to purchase shares of restricted
stock at a premium to the recent trading price shows our faith in the future
prospects of the Company. All of us feel that even at a premium,
NeoGenomics is an excellent investment opportunity.”
About
NeoGenomics, Inc.
NeoGenomics,
Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in
cancer genetics diagnostic testing, the fastest growing segment of the
laboratory industry. The company’s testing services include
cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,
morphology studies, anatomic pathology and molecular genetic
testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists,
oncologists, urologists, and hospitals throughout the United States. For
additional information about NeoGenomics, visit http://www.neogenomics.org.
For more
news and information on NeoGenomics, please visit www.IRGnews.com/coi/NGNM
where you can find a fact sheet on the company, investor presentations, and
more. Interested parties can also access additional investor
relations material, including an investment profile and an equity research
report, from Hawk Associates at http://www.hawkassociates.com or from the American Microcap
Institute at http://www.americanmicrocapinstitute.com/ngnm/.
For
further information, please contact:
|
NeoGenomics,
Inc.
|
The
Investor Relations Group
|
|
Steven
C. Jones
|
Investor
Relations:
|
|
Director
of Investor Relations
|
Dillon
Heins
|
|
(239)
325-2001
|
(212)
825-3210
|
| sjones@neogenomics.com | dheins@investorrelationsgroup.com |
|
or
|
|
|
Hawk
Associates, Inc.
|
Media
Relations:
|
|
Ms.
Julie Marshall
|
Janet
Vasquez
|
|
(305)-451-1888
|
(212)
825-3210
|
| neogenomics@hawkassociates.com | jvasquez@investorrelationsgroup.com |